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Within	the	next	25	years,	an	estimated	1	billion	women	
worldwide will be older than 50 years, and therefore 
likely to be nearing menopause or postmenopausal.1 
Hot flushes (vasomotor symptoms) are experienced by 
approximately 73% of postmenopausal women, and the 
associated sleep disturbances, fatigue, and decreased 
cognitive function lead to a reduction in their quality 
of life and an increased use of medical resources.2 A 
hypothalamic mechanism is well established in the 
understanding of hot flushes,3 but the pathways involved 
have been unclear, thus reducing therapeutic options. 
Novel	 hypothalamic	 neuropeptide-signalling	 pathways	
have shed light on the central regulation of both 
reproductive and thermoregulatory systems and the links 
between them,4 and might now lead to specific therapies.
The menopause results in oestrogen deficiency, with loss 
of feedback regulation of hypothalamic gonadotropin-
releasing	 hormone	 (GnRH).	 The	 kisspeptin–neurokinin	
B	 (NKB)–dynorphin	 (KNDy)	 signalling	 system	 in	 the	
hypothalamus is the proximate and obligate stimulus 
of	 GnRH	 secretion,	 and	 is	 hypertrophied	 after	 the	
menopause.4,5	 Hypothalamic	 NKB	 neurons	 also	 project	
to the medial preoptic area, the hypothalamic site of 
thermoregulatory neuronal pathways, and evidence 
exists	that	these	NKB	neurons	are	a	key	link	between	the	
endocrine changes of the menopause and vasomotor 
symptoms.4 Flushing, like thermoregulation, is controlled 
centrally but effected peripherally, and blood flow to 
the skin is also increased in postmenopausal women 
with severe flushing.6	NKB	neurons	might	 also	 facilitate	
cutaneous vasodilatation and contribute to oestrogenic 
modulation of body temperature.7
In The Lancet,	 Julia	 Prague	 and	 colleagues8 report 
the findings from their phase 2, randomised, double-
blind, placebo-controlled trial investigating the oral 
neurokinin	3	receptor	(NK3R)	antagonist	MLE4901	as	a	
new therapy for menopausal hot flushes. In 28 healthy 
women aged 40–62 years, oral administration of a 
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40 mg dose twice per day for 4 weeks reduced the 
number of hot flushes during week 4 by 45 percentage 
points (95% CI 22–67) compared with placebo 
(intention-to-treat	 adjusted	 means:	 placebo	 49·01	
[95% CI 40·81–58·56] vs MLE4901 19·35 [15·99–
23·42]; adjusted estimate of difference 29·66 [17·39–
42·87]; p<0·0001). This finding was also supported 
by an objective assessment of flushes, using the Bahr 
sternal skin conductance monitor. Reductions in the 
number of flushes might be less important to women 
than measures of quality of life, thus it is of interest 
that the authors found hot flush severity, bother, 
and interference to be significantly reduced during 
treatment with MLE4901. However, in Prague and 
colleagues’ study, no improvements occurred in the 
sexual symptoms commonly reported after menopause 
(MENQOL	 sexual	 domain	 score	 adjusted	 means:	
placebo 2·15 [95% CI 1·84–2·51] vs MLE4901 1·98 
[1·68-2·30];	 p=0·24).	 As	 an	 index	 of	 GnRH	 secretion,	
luteinising hormone pulse frequency was unchanged 
in the treatment group, although other measures of 
pulsatile secretion altered with increases in amplitude 
and orderliness of luteinising hormone pulse. Thus, 
although	 NKB	 pathways	 regulate	 both	 the	 vasomotor	
and reproductive systems, separate effects can be 
identified, and these might vary with the endocrine 
environment. Most withdrawals from the study were 
for reasons unrelated to treatment, and no serious 
adverse events occurred with MLE4901, although 
three women developed liver enzyme elevations 
(alanine aminotransferase was 4·5–5·9 times the upper 
limit of normal), which normalised within 90 days. 
The limitations of the trial include its small size (of 
68 women screened, only 28 completed the trial and 
were included in the per-protocol analysis) and short 
duration of treatment.
The current gold-standard treatment for menopausal 
hot flushes is oestrogen, but in some women its 
maximum efficacy might take many weeks to achieve.9 
Selective serotonin-reuptake inhibitors are a non-
hormonal alternative with similar improvements in 
flush reduction,10 but might not be well tolerated. 
And, although oestrogen is an effective treatment 
for flushing, oestrogen-free therapies are necessary 
for women with breast cancer. The severity of hot 
flushes in these women might be a major contributor 
to reduced adherence to the recommended 10 years of 
endocrine therapy, increasing recurrence and mortality.11 
Additionally, hot flushes are not the sole preserve of 
women:	44–80%	of	men	treated	for	advanced	prostate	
cancer have hot flushes, and 25% describe them as the 
most significant adverse effect on their quality of life.12
Although the role of oestrogen in the maintenance 
of bone and cardiovascular health is crucial to post-
reproductive health and quality of life during older age, 
vasomotor symptoms are the most commonly reported, 
and often the most acutely distressing, symptom of 
menopause.	Therefore,	NKB	antagonists	are	an	exciting	
development in an area in which the last development 
in mechanistic understanding is more than 20 years old. 
Larger trials of clinically relevant duration examining 
benefits relative to established treatments are needed 
and might lead to a much needed addition to a very 
small toolbox of treatments for hot flushes. 
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Paralysis of the arms and hands due to disease or 
trauma	 of	 the	 CNS	 greatly	 impairs	 the	 quality	 of	 life	
of millions of individuals. Therapies that replace lost 
neurons or repair severed connections hold great 
promise, but are probably years away from clinical 
deployment.	 Neuroprosthetics	 offer	 an	 alternative	
approach to restoring function, without relying 
on repair of damaged tissue, that is based on two 
fundamental premises. The first premise is that 
when we move a body part, or even imagine moving, 
moment-to-moment information that describes the 
movement can be decoded from measurements of the 
electrical activity in certain regions of the brain.1 Even 
in	 individuals	 who	 can	 no	 longer	 move	 due	 to	 CNS	
damage, desired movements are still represented in 
the activity of cortical neurons.2 This information can 
be transformed with mathematical algorithms into 
signals that can control a device outside the body. This 
strategy has enabled human subjects in laboratory 
settings to control, in real time, computer cursors or 
robotic arms with brain activity.3–5 The effectiveness 
of such brain–machine interfaces is dependent on the 
second	premise:	the	brain	can	modify	its	activity	on	the	
basis of feedback about the success of the movement, 
to improve performance.6 Over an individual’s lifetime, 
the brain learns patterns of activity that produce 
accurate, smooth movements of the person’s own 
body. But the brain is remarkably adaptable and can 
learn to generate new patterns appropriate for the 
control of an external device, with actuators and 
mechanical properties that behave differently to 
muscle, tendons, and joints.
An even more ambitious neuroprosthetic uses 
decoded brain activity to reanimate paralysed limbs. 
Electrical current applied to muscles, peripheral 
nerves, or the spinal cord can contract muscles in a 
controlled manner.7	 The	 goal	 is	 futuristic:	 a	 paralysed	
individual thinks about moving her arm as if her brain 
and muscles were not disconnected, and implanted 
technology seamlessly executes the desired movement. 
Both fundamental premises apply, but this type of 
neuroprosthetic requires the technology not only to 
record and decode neural signals, but to interface with 
the body’s motor system to produce complex patterns 
of muscle contractions. Results of only a few studies in 
animals8,9 and one in human beings10 have shown the 
feasibility of this approach. 
In The Lancet, Abidemi Bolu Ajiboye and colleagues11 
have advanced the ability of a neuroprosthetic to 
reanimate a paralysed limb. They report the experience 
of a man with a functionally complete C4 spinal 
cord injury using a brain–machine interface to make 
purposeful reaching and grasping movements. He 
received implants of 192 microelectrodes in motor 
cortex to record the activity of many neurons, and 
36 percutaneous electrodes for electrically stimulating 
hand and arm muscles. A novel algorithm mapped 
brain activity to stimulus parameters that produced 
specific joint movements. The participant learned to 
modulate cortical activity to move his arm to targets 
presented in a virtual-reality environment, and to 
reach, grasp, and drink from a cup of coffee and 
use a fork to eat mashed potatoes. After practising, 
he acquired and held virtual targets with 80–100% 
success, with reasonable speed, and without strong 
mental	exertion.	Without	the	brain–machine	interface,	
he was unable to perform any useful movements.
This study is groundbreaking as the first report of a 
person executing functional, multijoint movements 
of a paralysed limb with a motor neuroprosthesis. 
However, this treatment is not nearly ready for use 
outside the lab. The movements were rough and slow 
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